Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.

OBJECTIVE Interferon-alpha (IFNalpha) has been implicated in the pathogenesis of juvenile dermatomyositis (DM). The aim of this study was to examine serum IFNalpha activity in a cohort of children with juvenile DM to determine relationships between IFNalpha and indicators of disease activity and severity. METHODS Thirty-nine children with definite/probable juvenile DM were included in the study. Serum samples were obtained at the time of diagnosis from 18 untreated patients with juvenile DM. Second samples from 11 of these patients were obtained at 24 months, while they were receiving treatment, and third samples were obtained from 7 of these patients at 36 months. The remaining 21 children were studied 36 months after their initial diagnosis. Serum IFNalpha activity was measured using a functional reporter cell assay. RESULTS Patients with juvenile DM had higher serum IFNalpha activity than both pediatric and adult healthy control subjects. In untreated patients, serum IFNalpha activity was positively correlated with serum muscle enzyme levels (P<0.05 for creatine kinase, aspartate aminotransferase, and aldolase) and inversely correlated with the duration of untreated disease (P=0.017). The tumor necrosis factor alpha -308A allele was associated with higher serum IFNalpha levels only in untreated patients (P=0.030). At 36 months, serum IFNalpha levels were inversely correlated with muscle enzyme levels in those patients still requiring therapy and with the skin Disease Activity Score in those patients who had completed therapy (P=0.002). CONCLUSION Serum IFNalpha activity was associated with higher serum levels of muscle-derived enzymes and a shorter duration of untreated disease in patients with newly diagnosed juvenile DM and was inversely correlated with measures of chronic disease activity at 36 months postdiagnosis. These data suggest that IFNalpha could play a role in disease initiation in juvenile DM.

[1]  T. Niewold,et al.  The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. , 2008, Arthritis and rheumatism.

[2]  J. Harley,et al.  Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. , 2008, Arthritis and rheumatism.

[3]  Yi-Wen Chen,et al.  Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis , 2008, BMC Immunology.

[4]  B. Feldman,et al.  Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood , 2008, The Lancet.

[5]  B. Feldman,et al.  Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset. , 2008, Rheumatology.

[6]  M. Crow,et al.  A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies , 2008, Annals of the rheumatic diseases.

[7]  J. Buyon,et al.  Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. , 2008, Arthritis and rheumatism.

[8]  A. Paller,et al.  Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. , 2008, Arthritis and rheumatism.

[9]  C. Kallenberg,et al.  Type I interferons are involved in the development of ultraviolet B-induced inflammatory skin lesions in systemic lupus erythaematosus patients , 2007, Annals of the rheumatic diseases.

[10]  S. Pillemer,et al.  Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. , 2007, Arthritis and rheumatism.

[11]  S. Kong,et al.  Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. , 2007, Arthritis and rheumatism.

[12]  J. Harley,et al.  High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus , 2007, Genes and Immunity.

[13]  P. Gregersen,et al.  An Interferon Signature in the Peripheral Blood of Dermatomyositis Patients is Associated with Disease Activity , 2007, Molecular medicine.

[14]  Sharon Adams,et al.  Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. , 2006, Arthritis and rheumatism.

[15]  L. Pachman,et al.  MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. , 2006, Clinical immunology.

[16]  A. Takaoka,et al.  Interferon signalling network in innate defence , 2006, Cellular microbiology.

[17]  M. Crow,et al.  Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. , 2006, Arthritis and rheumatism.

[18]  M. Peterson,et al.  Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. , 2005, Arthritis and rheumatism.

[19]  A. Dyer,et al.  History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. , 2005, Arthritis and rheumatism.

[20]  L. Rönnblom,et al.  Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. , 2005, Arthritis and rheumatism.

[21]  V. Pascual,et al.  Cross-regulation of TNF and IFN-¿ in autoimmune diseases , 2005 .

[22]  R. Bode,et al.  Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. , 2003, Arthritis and rheumatism.

[23]  C. Berry,et al.  Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. , 2002, Arthritis and rheumatism.

[24]  Eric P. Hoffman,et al.  Gene Expression Profiling in DQA1*0501+ Children with Untreated Dermatomyositis: A Novel Model of Pathogenesis1 , 2002, The Journal of Immunology.

[25]  F. Lund-Johansen,et al.  Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. , 2001, The American journal of pathology.

[26]  L. Pachman,et al.  TNFα-308A allele in juvenile dermatomyositis: Association with increased production of tumor necrosis factor α, disease duration, and pathologic calcifications , 2000 .

[27]  R. Zawatzky,et al.  Failure to Detect Antiviral Activity in Serum and Plasma of Healthy Individuals Displaying High Activity in ELISA for IFNWOLFRAM alpha beta and IFNral , 1999 .

[28]  R. Albertini,et al.  Association among somatic HPRT mutant frequency, peripheral blood T-lymphocyte clonality, and serologic parameters of disease activity in children with juvenile onset dermatomyositis. , 1999, Clinical immunology.

[29]  A. Dyer,et al.  New-onset juvenile dermatomyositis: comparisons with a healthy cohort and children with juvenile rheumatoid arthritis. , 1997, Arthritis and rheumatism.

[30]  M. Christensen,et al.  Lack of detection of enteroviral RNA or bacterial DNA in magnetic resonance imaging-directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis. , 1995, Arthritis and rheumatism.

[31]  S. Albani,et al.  Recurrent juvenile dermatomyositis and cutaneous necrotizing arteritis with molecular mimicry between streptococcal type 5 M protein and human skeletal myosin. , 1992, The Journal of pediatrics.

[32]  C. Ober,et al.  Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501. , 1991, Human immunology.

[33]  V. Dubowitz,et al.  DERMATOMYOSITIS, POLYMYOSITIS, AND COXSACKIE-B-VIRUS INFECTION , 1987, The Lancet.

[34]  J. Friedman,et al.  Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. , 1986, Arthritis and rheumatism.

[35]  H. Moutsopoulos,et al.  Detection of anti-interferon antibodies in systemic lupus erythematosus. , 1983, Clinical and experimental rheumatology.

[36]  T. Schnitzer,et al.  Serum interferon levels in patients with systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[37]  A. Notkins,et al.  Immune interferon in the circulation of patients with autoimmune disease. , 1979, The New England journal of medicine.

[38]  J. Brody,et al.  Antibody levels to parainfluenza, rubella, measles, and influenza A virus in children with polymyositis. , 1975, Arthritis and rheumatism.

[39]  F. Oechsli.  Letter: Oral contraception and sex ratio at birth. , 1974, Lancet.